MXPA03001202A - Metodo para afectar el sueno y comportamientos relacionados con el sueno. - Google Patents

Metodo para afectar el sueno y comportamientos relacionados con el sueno.

Info

Publication number
MXPA03001202A
MXPA03001202A MXPA03001202A MXPA03001202A MXPA03001202A MX PA03001202 A MXPA03001202 A MX PA03001202A MX PA03001202 A MXPA03001202 A MX PA03001202A MX PA03001202 A MXPA03001202 A MX PA03001202A MX PA03001202 A MXPA03001202 A MX PA03001202A
Authority
MX
Mexico
Prior art keywords
sleep
adrenocortical hormone
level
reducing
affecting
Prior art date
Application number
MXPA03001202A
Other languages
English (en)
Spanish (es)
Inventor
Benjamin Carl Wiegand
Original Assignee
Johnson & Johnson Consumer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson & Johnson Consumer filed Critical Johnson & Johnson Consumer
Publication of MXPA03001202A publication Critical patent/MXPA03001202A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4806—Sleep evaluation
    • A61B5/4815—Sleep quality
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2228—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0016—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the smell sense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0022—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the tactile sense, e.g. vibrations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0027—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the hearing sense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0044—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus by the sight sense
MXPA03001202A 2002-02-08 2003-02-07 Metodo para afectar el sueno y comportamientos relacionados con el sueno. MXPA03001202A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0203045.0A GB0203045D0 (en) 2002-02-08 2002-02-08 Method of afefecting sleep and sleep-related behaviours

Publications (1)

Publication Number Publication Date
MXPA03001202A true MXPA03001202A (es) 2004-09-06

Family

ID=9930734

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001202A MXPA03001202A (es) 2002-02-08 2003-02-07 Metodo para afectar el sueno y comportamientos relacionados con el sueno.

Country Status (10)

Country Link
US (2) US20030225095A1 (US20070275102A9-20071129-P00001.png)
EP (1) EP1342489A1 (US20070275102A9-20071129-P00001.png)
JP (1) JP2003260138A (US20070275102A9-20071129-P00001.png)
KR (1) KR20030067595A (US20070275102A9-20071129-P00001.png)
CN (1) CN1457902A (US20070275102A9-20071129-P00001.png)
BR (1) BR0300301A (US20070275102A9-20071129-P00001.png)
CA (1) CA2417305A1 (US20070275102A9-20071129-P00001.png)
GB (1) GB0203045D0 (US20070275102A9-20071129-P00001.png)
MX (1) MXPA03001202A (US20070275102A9-20071129-P00001.png)
TW (1) TW200514558A (US20070275102A9-20071129-P00001.png)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2384563A (en) * 2002-01-29 2003-07-30 Johnson & Johnson Consumer Method of measuring the stress or relaxation level of a mammal
KR100691860B1 (ko) * 2003-12-08 2007-03-12 주식회사 대양이앤씨 산란계의 산란율을 증가시키는 음원 시스템
US20060019224A1 (en) * 2004-07-23 2006-01-26 Pics, Inc. Insomnia assessment and treatment device and method
GB2418143B (en) * 2004-09-21 2010-03-17 Can Do Corp Ltd Apparatus for behaviour modification
US9131079B2 (en) 2005-02-07 2015-09-08 Robert A. Oklejas System and method for providing a television network customized for an end user
US10219035B2 (en) 2005-02-07 2019-02-26 Robert A. Oklejas System and method for providing a television network customized for an end user
US8151315B2 (en) * 2005-02-07 2012-04-03 Oklejas Robert A Hybrid audio/video entertainment system
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
US20070150310A1 (en) * 2005-12-27 2007-06-28 Benjamin Wiegand A method of motivating an individual to improve lifestyle factors
US20070150204A1 (en) * 2005-12-27 2007-06-28 Benjamin Wiegand Methods for recommending a program to improve or maintain pro-inflammatory immune health
US20070150205A1 (en) * 2005-12-27 2007-06-28 Benjamin Wiegand Methods for assessing the pro-inflammatory immune health of an individual
US20070150203A1 (en) * 2005-12-27 2007-06-28 Benjamin Wiegand A kit for assessing the pro-inflammatory immune health of an individual
US20070150202A1 (en) * 2005-12-27 2007-06-28 Benjamin Wiegand A method for assessing the efficacy of a program to improve or maitain the pro-inflammatory immune health
US20070270393A1 (en) * 2006-02-17 2007-11-22 Theresa Buckley Methods and compositions for modulation of sleep cycle
US20100048984A1 (en) * 2008-08-21 2010-02-25 Anderson Troy G Integrated Sleep Aid Control Center and Method Therefor
WO2014115053A1 (en) * 2013-01-23 2014-07-31 Koninklijke Philips N.V. Means for assisting human information processing
JP6488485B2 (ja) * 2014-09-19 2019-03-27 ソニー株式会社 状態制御装置、状態制御方法、および状態制御システム
WO2018045483A1 (zh) * 2016-09-06 2018-03-15 深圳市赛亿科技开发有限公司 睡眠辅助系统
US20200360654A1 (en) * 2019-05-17 2020-11-19 Karen Hanlon Grove System and method for a therapeutic box
CN116150591B (zh) * 2023-04-04 2023-06-20 安徽星辰智跃科技有限责任公司 一种睡眠感官应激水平检测量化的方法、系统和装置

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1019866B (it) * 1974-08-09 1977-11-30 Biomedix Ag Apparecchiatura per la determinazio ne della concentrazione di emoglobi na totale ossigenata e risotta car bossiemoglobina del la capacita dell emoglobina per lo ossigeno della saturazione per centuale in ossigeno e in ossido di carbonio nel sangue o in solu zioni di emoglobina
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
EP0053754B1 (de) * 1980-12-06 1986-04-23 Reichert, Dietrich, Dr. med. Mittel zur Bekämpfung des Schnarchens und Verfahren zu dessen Anwendung
US4375421A (en) * 1981-10-19 1983-03-01 Lever Brothers Company Viscous compositions containing amido betaines and salts
LU84752A1 (fr) * 1983-04-15 1984-11-28 Oreal Composition lavante et moussante a base d'agents tensio-actifs et de polymeres anioniques
LU84753A1 (fr) * 1983-04-15 1984-11-28 Oreal Composition lavante et moussante a base d'agents tensio-actifs non ioniques et de polymeres anioniques
US4670463A (en) * 1984-11-14 1987-06-02 Yale University Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions
JPS61267526A (ja) * 1984-11-14 1986-11-27 インタ−ナシヨナル　フレイバ−ス　アンド　フレグランシス　インコ−ポレイテツド 人間のストレスに対する生理的及び、又は主観的反応性を減少させる医薬
US4671959A (en) * 1984-11-14 1987-06-09 Yale University Method of causing the reduction of physiological and/or subjective reactivity to stress in humans being subjected to stress conditions
EP0269107A3 (en) * 1986-11-28 1989-10-11 Kao Corporation Composition for hair treatment agent
US4877322A (en) * 1987-04-30 1989-10-31 Eyedentify, Inc. Method and apparatus for measuring blood oxygen levels in selected areas of the eye fundus
FR2632519B1 (fr) * 1988-06-14 1992-02-21 Oreal Composition parfumante, a phase aqueuse continue, ayant une forte concentration en parfum
US5564417A (en) * 1991-01-24 1996-10-15 Non-Invasive Technology, Inc. Pathlength corrected oximeter and the like
US5711899A (en) * 1988-12-23 1998-01-27 Henkel Kommanditgesellschaft Auf Aktien Free flowing pearlescent concentrate
DE3930725A1 (de) * 1989-09-14 1991-03-21 Benckiser Gmbh Joh A Extra-milde duschgel- und haarshampoo-formulierung mit niedriger tensidkonzentration
US5063062A (en) * 1989-09-27 1991-11-05 D. Greenspan Cleaning compositions with orange oil
AU630561B2 (en) * 1990-06-12 1992-10-29 Cathy Palou A therapeutic preparation containing myrrh for treating skin disorders
US5614553A (en) * 1990-07-06 1997-03-25 Albion Laboratories, Inc. Composition and method for alleviating stress in warm-blooded animals
US5304112A (en) * 1991-10-16 1994-04-19 Theresia A. Mrklas Stress reduction system and method
US5275761A (en) * 1992-04-15 1994-01-04 Helene Curtis, Inc. Conditioning shampoo composition and method of preparing and using the same
US5403263A (en) * 1992-05-21 1995-04-04 P.I.P. Surgical Audiotape Series, Inc. Method of reducing the recovery time and stress associated with surgery
US5284603A (en) * 1992-06-03 1994-02-08 Colgate Palmolive Co. Gelled detergent composition having improved skin sensitivity
US5497771A (en) * 1993-04-02 1996-03-12 Mipm Mammendorfer Institut Fuer Physik Und Medizin Gmbh Apparatus for measuring the oxygen saturation of fetuses during childbirth
US5403587A (en) * 1993-04-22 1995-04-04 Eastman Kodak Company Disinfectant and sanitizing compositions based on essential oils
US5578312A (en) * 1993-05-05 1996-11-26 Parrinello; Vincene M. Skin care system and method for improving moisture retention in skin
GB9321479D0 (en) * 1993-10-18 1993-12-08 Scotia Holdings Plc Stabilisation of polyunsaturates
US5597406A (en) * 1993-11-02 1997-01-28 Henkel Corporation Method of thickening aqueous formulations
US5501813A (en) * 1993-11-02 1996-03-26 Henkel Corporation Thickener for aqueous compositions
US5466446A (en) * 1994-02-16 1995-11-14 Stiefel Laboratories, Inc. Topical compositions containing bensoyl peroxide and clindamycin and method of use thereof
DE4416566A1 (de) * 1994-05-11 1995-11-16 Huels Chemische Werke Ag Wäßrige viskoelastische Tensidlösungen zur Haar- und Hautreinigung
MX9605996A (es) * 1994-05-31 1997-12-31 Procter & Gamble Composiciones limpiadoras.
US5540853A (en) * 1994-10-20 1996-07-30 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US5849310A (en) * 1994-10-20 1998-12-15 The Procter & Gamble Company Personal treatment compositions and/or cosmetic compositions containing enduring perfume
US5716919A (en) * 1995-05-09 1998-02-10 The Andrew Jergens Company Mild cleansing formulation with a hydroxy-containing compound, a nonionic surfactant and an anionic surfactant
US5607980A (en) * 1995-07-24 1997-03-04 The Procter & Gamble Company Topical compositions having improved skin feel
US5771261A (en) * 1995-09-13 1998-06-23 Anbar; Michael Telethermometric psychological evaluation by monitoring of changes in skin perfusion induced by the autonomic nervous system
US5855884A (en) * 1995-11-27 1999-01-05 Kos Pharmaceuticals, Inc. Treatment of stress-induced migraine headache with a corticotropin releasing hormone blocker
JPH09227399A (ja) * 1996-02-27 1997-09-02 Pola Chem Ind Inc 副腎皮質ホルモン分泌抑制剤
JPH09227400A (ja) * 1996-02-28 1997-09-02 Pola Chem Ind Inc 副腎皮質ホルモン分泌抑制剤
US5904916A (en) * 1996-03-05 1999-05-18 Hirsch; Alan R. Use of odorants to alter learning capacity
US5792739A (en) * 1996-04-24 1998-08-11 Lever Brothers Company, Division Of Conopco, Inc. Liquid compositions comprising hydrophobically modified polyalkylene glycols as mildness actives
US5789953A (en) * 1996-05-29 1998-08-04 Integrated Device Technology, Inc. Clock signal generator providing non-integer frequency multiplication
US5804538A (en) * 1996-06-20 1998-09-08 The Procter & Gamble Company Perfume delivery systems in liquid personal cleansing compositions
US5753637A (en) * 1996-10-09 1998-05-19 Ideal Ideas, Inc. Method of treating acne conditions
US5922331A (en) * 1997-03-26 1999-07-13 Chanel, Inc. Skin cream composition
US5958462A (en) * 1997-05-23 1999-09-28 Mclean; Linsey Therapeutic bath salts and method of use
US5916576A (en) * 1997-05-30 1999-06-29 Amway Corporation Method of scavenging free radicals using orange extract
JPH1119076A (ja) * 1997-07-07 1999-01-26 Pola Chem Ind Inc 香りの抗ストレス効果の測定法
JPH1123579A (ja) * 1997-07-07 1999-01-29 Pola Chem Ind Inc マッサージの評価方法
EP1012151B1 (en) * 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
US5980925A (en) * 1997-12-30 1999-11-09 Ethicon, Inc. High glycerin containing anti-microbial cleansers
JP2000053532A (ja) * 1998-08-04 2000-02-22 Shiseido Co Ltd 美容法
US6432989B1 (en) * 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
EP1218023B8 (en) * 1999-10-01 2006-05-03 Johnson & Johnson Consumer Companies, Inc. Method for calming human beings using personal care compositions
DE19952970A1 (de) * 1999-11-03 2001-05-31 Peter Neuhaus Der Entspannung,dem Relaxen oder der Meditation dienende Pyramide
US20020090664A1 (en) * 2000-12-20 2002-07-11 Benjamin Wiegand Methods for measuring stress in mammals
US20020146469A1 (en) * 2000-12-20 2002-10-10 Benjamin Wiegand Methods for reducing chronic stress in mammals
US20020151527A1 (en) * 2000-12-20 2002-10-17 Benjamin Wiegand Method for reducing acne or improving skin tone
US6428466B1 (en) * 2001-02-14 2002-08-06 Simulated Environment Concepts, Inc. Spa capsule
US20030005409A1 (en) * 2001-07-02 2003-01-02 Pradeep Tumati System and method for modifying software without halting its execution
GB2384563A (en) * 2002-01-29 2003-07-30 Johnson & Johnson Consumer Method of measuring the stress or relaxation level of a mammal
US20040175438A1 (en) * 2003-03-03 2004-09-09 Benjamin Wiegand Methods for alleviating symptoms associated with menopause using sensory regimen

Also Published As

Publication number Publication date
KR20030067595A (ko) 2003-08-14
CN1457902A (zh) 2003-11-26
GB0203045D0 (en) 2002-03-27
CA2417305A1 (en) 2003-08-08
JP2003260138A (ja) 2003-09-16
EP1342489A1 (en) 2003-09-10
TW200514558A (en) 2005-05-01
US20070275102A9 (en) 2007-11-29
US20030225095A1 (en) 2003-12-04
US20070149492A1 (en) 2007-06-28
BR0300301A (pt) 2004-08-03

Similar Documents

Publication Publication Date Title
MXPA03001202A (es) Metodo para afectar el sueno y comportamientos relacionados con el sueno.
Chrcanovic et al. Factors influencing the fracture of dental implants
FR2833177B1 (fr) Dispositif medical actif comprenant des moyens perfectionnes de discrimination des phases d'eveil et de sommeil
Wilse et al. Awakenings and the return to sleep in an older population
DE69325998D1 (de) Verwendung von beta-hydroxy-beta-methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
WO2005051396A3 (en) Methods for reducing body fat using vitamin d compounds
NZ566083A (en) Methods and compositions for prevention and treatment of diabetic and aged skin
FR2739782B1 (fr) Dispositif medical implantable actif, notamment stimulateur cardiaque, a fonctionnement asservi et consommation reduite
SG170058A1 (en) Methods of treating inflammatory and autoimmune diseases with natalizumab
WO2003040686A3 (en) Dosing and administration of therapeutic micro-organs in living subjects and devices and methods for same
WO2006062559A3 (en) Device for enhancing tissue glucose processing
EP3199172A8 (en) Dosing regimen for multiple sclerosis
MXPA05007470A (es) Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.
Brandenberger et al. The 24‐h growth hormone rhythm in men: sleep and circadian influences questioned
AU5104198A (en) Use of conjugated linoleic acid to enhance natural killer lymphocyte function
YU30002A (sh) Upotreba dipiridamola ili mopidamola u pripremanju leka za lečenje i prevenciju mikrocirkulacionih poremećaja koji zavise od fibrina
EP1136098A3 (en) System and method of automatically adjusting auto capture safety margin
TW200510020A (en) Methods for alleviating symptoms associated with menopause using sensory regimen
WO2002049629A3 (en) Methods for reducing chronic stress in mammals
EP0290262A3 (en) Improved nitrate therapy for angina pectoris
MXPA05009242A (es) Tratamiento de la diabetes tipo 1 con los inhibidores de la pde5.
EP1622450A4 (en) PROCESS FOR PROMOTING UNINTERRUPTED SLEEP BY ADMINISTERING TROPIUM CHLORIDE
ATE509650T1 (de) Insulin zur verwendung in einem dosierverfahren
EP1123100A4 (en) MEMORY IMPROVEMENT BY ADMINISTRATION OF DELTA-5-ANDROSTEN-3-BETA-OL-7,17-DION AND 3-BETA-ESTERS THEREOF
TW200613032A (en) Uses for augmenting bone